The US Food and Drug Administration (FDA) on Friday authorized the emergency use of Moderna and Pfizer-BioNTech’s COVID-19 vaccines for children as young as 6 months of age, asserting that the ...

Moderna (NASDAQ:MRNA) stock is jumping again. Shares are up 9% today, trading near $57 in the Tuesday afternoon session. That extends a remarkable 2026 run for the mRNA pioneer. The move pushes ...

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up 14% to $68 and change in afternoon trading Friday, extending a ...

Pfizer is by far the larger and better-established drugmaker. With a market cap of $156 billion, the pharmaceutical leader boasts a deep product portfolio across several therapeutic areas. Even with a ...

The study also reviews the great potential of mRNA vaccines to treat influenza, RSV, cancer, and autoimmune diseases.

Senator Ron Johnson (R-WI) made controversial claims during a June 2026 Senate hearing, alleging that federal health agencies ...

The US Food and Drug Administration (FDA) on Wednesday authorized bivalent COVID-19 vaccines targeting the Omicron BA.4/5 subvariants developed by Pfizer-BioNTech and Moderna, asserting that the ...

The mRNA vaccines approved to treat COVID-19 are safe and effective and show promise in treating other diseases including ...

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has ...

From oncology to obesity, Pfizer bets big on India for its next growth wave Pfizer is prioritizing India for future growth.

The smaller, more volatile of these two companies has higher potential for significant gains. However, that also comes with a healthy dose of risk. Choosing between these two stocks may come down to ...